January 2026 Research Update

Across this group of studies, the main pattern was that MDA5 antibody-positive dermatomyositis with lung involvement is not one single condition. Several research teams identified subgroups with very different risks of rapidly progressive interstitial lung disease (fast-worsening scarring/inflammation in the lungs) and early death, using chest scans, blood tests, and symptom patterns. [1] [2] [3] [4] [5] [6]

One scan-based study compared several visual scoring methods on high-resolution chest CT and found one scoring approach was the strongest single CT predictor of rapidly progressive lung disease, with moderate accuracy, and it also tracked with worse breathing test results. The same study built a combined risk tool (a nomogram) that used CT features plus clinical factors such as fever, age, sex, and C-reactive protein, and this combined model separated higher- and lower-risk groups better than CT scoring alone in their dataset. [1]

Multiple blood-test approaches pointed in a similar direction: lower lymphocyte (immune cell) counts and higher inflammation ratios tended to cluster in patients with more rapidly progressive lung disease and higher short-term death rates. In one larger cohort, clustering based on lymphocyte subsets separated a higher-risk group (lower T cells, B cells, and natural killer cells) from a lower-risk group, and the higher-risk cluster had more rapidly progressive lung disease and higher death rates at 3 and 6 months. [2] [3]

Some smaller studies suggested that changes over time in specific blood markers may help track risk, but this remains exploratory. Serial ferritin patterns (trajectories) were reported to predict mortality risk, and in a 24-person study, interferon-lambda 3 levels dropped within 1 month in people whose lung disease was controlled over a year but stayed high in those with poor control, including higher values among those who later died. [4] [5]

Who a person is and how dermatomyositis shows up in the body may also relate to lung risk. In a Japanese multicenter cohort, a small subgroup with MDA5-positive interstitial lung disease but without typical skin or muscle symptoms had the poorest overall prognosis, and within this subgroup, rapidly progressive lung disease aligned with higher MDA5 antibody levels. [7]

Looking beyond dermatomyositis alone, a Canadian clinic cohort across several inflammatory muscle diseases found that a later pattern called postmyopathic progressive pulmonary fibrosis occurred in a minority overall and was more common in MDA5-positive dermatomyositis and antisynthetase syndrome than in scleromyositis. This postmyopathic progressive fibrosis group also showed more rapid progression, more lung transplants, and more frequent rituximab use, suggesting it represents a higher-risk lung trajectory in real-world care. [8]

A separate North American single-center experience following patients for up to several years reported that lung function and CT scan changes improved over time in many patients receiving combination immune-suppressing treatment, although a few still died early from rapidly progressive disease. This study also reported that certain immune signals in blood (such as interleukin-15 and paraoxonase-1 activity) tracked with disease activity, but these biomarker results were exploratory. [9]

Not all shortness of breath in dermatomyositis is caused by interstitial lung disease, which matters when thinking about prediction and risk. One case report described a woman whose worsening breathing was first treated as pneumonia, but later imaging did not show interstitial lung disease, and respiratory muscle weakness was identified as the likely cause of her symptoms. [10]

Finally, a commentary highlighted that even when patients all have MDA5-positive dermatomyositis with CT-confirmed lung disease, data-driven clustering can separate very high- and very low-risk phenotypes, with large differences in early death rates. It also emphasized that differences in antibody testing methods can complicate how confidently results can be applied across hospitals and countries. [6]

For patients and caregivers, this set of studies mainly provides background on why doctors and researchers talk about "higher-risk" and "lower-risk" patterns in MDA5 antibody-positive dermatomyositis with lung involvement: different combinations of CT scan features, routine blood counts, and inflammation markers may signal different chances of fast lung worsening. These tools are not yet uniform or standardized across centers, and several results come from small or single-center studies, so it is still uncertain which specific scoring systems or blood markers will be most reliable in everyday care and in diverse patient groups. [1] [2] [3] [4] [5] [7] [8] [9] [10] [6]

Across these papers, a consistent message was that no single blood test reliably captures every case of dermatomyositis or related inflammatory muscle disease. When common screening tests look negative or normal, other tests (different antibody methods, muscle imaging, biopsy, or nailfold capillary imaging) may still show patterns that fit the diagnosis or point to organ involvement. [11] [12] [13]

One case report described a person with dermatomyositis and interstitial lung disease who had a negative antinuclear antibody (ANA) test by indirect immunofluorescence, but a different test method (line immunoblot) detected anti-SSA/Ro52 antibodies. This illustrates that different lab methods can give different answers for ANA-related testing in the same patient. [11]

Another single-patient report described inflammatory muscle disease in an older man who had ongoing muscle weakness despite persistently normal creatine kinase (CK), a blood marker often used to look for muscle inflammation. In that case, Mi-2 antibodies were positive, MRI showed muscle swelling, and a muscle biopsy showed changes supporting inflammatory myopathy. [12]

In a moderate-sized cross-sectional study of 50 children with primary Raynaud's or juvenile connective tissue diseases (including juvenile dermatomyositis), nailfold videocapillaroscopy (a close-up look at small blood vessels at the fingernail) showed a "scleroderma pattern" significantly more often in juvenile systemic sclerosis than in either primary Raynaud's or juvenile dermatomyositis. Certain capillary changes were linked with organ issues: for example, higher avascular scores and very low capillary density were more common in children with interstitial lung disease. [13]

For patients and caregivers, these papers help explain why a clinician may use more than one kind of test when dermatomyositis or related conditions are suspected, especially if an initial blood test looks reassuring. Right now, the strongest, more general information here comes from the pediatric nailfold capillary study, while the ANA and normal-CK examples are single-patient reports that show what can happen but cannot tell how often it happens. It remains uncertain which combinations of tests work best in different age groups and symptom patterns, or how results should be interpreted in every individual situation. [11] [12] [13]

Across this group, the main pattern was exploratory evidence (case reports and lab studies) looking at targeted immune treatments for dermatomyositis complications, especially lung involvement and severe gastrointestinal blood-vessel problems. Results generally pointed toward reduced inflammation in the lungs in experimental settings and symptom improvement in a few individual children, but these reports cannot show how well these approaches work for most people. [14] [15] [16] [17]

In a mouse model of myositis-related interstitial lung disease (lung inflammation and scarring), baricitinib reduced lung inflammation and fibrosis. The study also suggested baricitinib may work by lowering certain immune processes linked to scarring in the lung in both animals and lung cells grown in the lab. [14]

In one 4-year-old with juvenile dermatomyositis who had anti-MDA5 antibodies (a blood marker sometimes linked with lung risk), baricitinib was added early to other treatments and the child improved over time, including muscle strength and skin symptoms, with the reported immune signature becoming undetectable. This is a single-patient report, so it cannot predict what will happen for others or fully define long-term safety. [16]

In one 3-year-old with juvenile dermatomyositis and interstitial lung disease, adding rituximab early alongside standard treatments was followed by improved muscle strength, improved skin activity scores, and improved lung findings on a chest scan, without serious side effects reported. Because this describes one child, it mainly adds clinical experience rather than proof of benefit. [15]

A separate report described two patients with anti-NXP2 dermatomyositis complicated by digestive vasculitis and gastrointestinal perforation who received eculizumab as rescue therapy, but details on outcomes were not available in the provided summary. This still signals that very severe gut and blood-vessel complications are being treated with highly targeted immune medicines in selected situations. [17]

For patients and caregivers, these studies mainly provide background on how some specialists are exploring targeted immune medicines for difficult complications like interstitial lung disease or severe gastrointestinal blood-vessel involvement. Right now, the evidence here is early (single-patient or two-patient reports, plus animal and lab work), so it does not tell how often these treatments help, who benefits most, or what the full risks are over time, especially in children. Larger, well-controlled clinical studies would be needed to answer those questions. [14] [15] [16] [17]

Two studies focused on skin symptoms and appearance in dermatomyositis, one looking at procedure-based care and one looking at how a potential anti-inflammatory medicine affects patient skin cells. Overall, the evidence suggested possible improvements in visible skin changes and reductions in an itch-related immune signal, but both lines of evidence are early and do not establish how well these approaches work across the wider dermatomyositis community. [18] [19]

In a small retrospective study that included 6 people with dermatomyositis (within a larger connective-tissue disease group), energy-based laser treatments were linked with improved skin redness and overall skin appearance scores, while changes in dyspigmentation were less clear in the dermatomyositis subgroup. Reported side effects such as bruising-like marks or blisters were described as temporary, and the authors did not observe disease reactivation during follow-up. [18]

In an ex vivo study using cells taken from dermatomyositis skin and blood, lenabasum reduced IL-31 (an immune signal linked with itch) produced by certain immune cell types, and this effect depended on the CB2 receptor. The response was stronger in skin-derived cells than in blood-derived cells, suggesting the local skin environment may shape inflammation and itch in dermatomyositis. [19]

For patients bothered by dermatomyositis skin changes or itch, these papers suggest two different research directions: supportive procedures (laser-based treatments aimed at redness or visible lesions) and medicines designed to reduce specific immune signals involved in itch. However, the clinical laser report was small and uncontrolled, and the lenabasum work was lab-based rather than a treatment trial, so it remains uncertain how durable the benefits are, which skin problems respond best, and what the tradeoffs are for different people. [18] [19]

Across studies, autoantibodies (immune proteins measured in blood) helped identify dermatomyositis subgroups with different organ risks and different long-term paths. The clearest pattern was that anti-NXP2 in juvenile dermatomyositis tracked with more severe muscle involvement and more complications, while anti-TIF1-gamma showed links to cancer risk in some settings and to harder-to-control disease in another. At the same time, large real-world data showed that many people still have high health care use over time, and antibody results are only one piece of the overall picture. [20] [21] [22] [23] [24]

In one longitudinal study of children and adults grouped by antibodies, children with anti-NXP2 had much higher muscle enzyme levels and lower muscle function scores at the start than other juvenile antibody groups and than adults with anti-NXP2. Over 3 years, this anti-NXP2 juvenile group also had more systemic complications (including swallowing problems, calcium deposits in tissues, heart involvement, and macrophage activation syndrome) and a higher risk of relapse, with muscle enzyme levels changing differently over time compared with other groups. [20]

A separate multicenter cohort of 201 people found that severe disease at diagnosis was common, and the type of organ involvement differed by age: symptomatic lung disease was more common in adults, while inflammation of gut blood vessels was more common in children. In that same study, anti-NXP2 in juvenile dermatomyositis was linked to higher odds of severe disease at diagnosis, while anti-Mi-2 in adult dermatomyositis was linked to lower odds of severe disease; by the last follow-up, inactive disease or remission rates were similar between juvenile-onset and adult-onset groups. Severe infections occurred in about one-quarter of patients in this cohort. [22]

Two studies focused on anti-TIF1-gamma. In a Taiwanese anti-TIF1-gamma-positive group, people with a strong anti-TIF1-gamma signal were more likely to have dermatomyositis and had a higher cancer rate than those with a weak signal, while having anti-Ro52 at the same time was associated with higher rates of lupus and lupus-Sjogren overlap. In a Mexican prospective cohort, anti-TIF1-g positivity was one of the factors included in a new index aimed at predicting dermatomyositis that stayed active despite standard therapy, but the tool still needs testing in other health systems. [21] [24]

A large US real-world analysis of newly diagnosed adults showed that myositis antibody testing was common but not universal, and only about one-third of those tested had a positive antibody result, with anti-TIF1-gamma and anti-NXP2 among the most frequent. Over time, this study also reported substantial steroid exposure, varied treatment approaches, and notable health care use, including hospitalizations and a measurable cumulative incidence of cancer over 3 years. [23]

For patients and caregivers, these studies support the idea that antibody results can help explain why dermatomyositis looks different from person to person, especially for children with anti-NXP2 who may face higher risks of relapse and certain complications over several years. For anti-TIF1-gamma, the studies here suggest it may sometimes travel with higher cancer rates or more persistent disease activity, but the strength of this link can vary by population and by how the antibody signal is measured. Overall, this evidence mainly helps with understanding long-term risk patterns rather than changing care on its own, and several results (like the refractory-disease index) still need confirmation in additional groups before they can be relied on broadly. [20] [21] [22] [23] [24]

This group of studies highlights that dermatomyositis can occasionally involve organs and complications outside the more familiar muscle and skin symptoms, including kidney disease, severe skin blistering, lymph node inflammation, and a specific small-blood-vessel complication affecting the blood. The evidence here is mainly from case reports and one small exploratory comparison study, so these events appear uncommon and the exact risks are still uncertain. A repeated pattern across reports was that these unusual complications occurred in the context of active, systemic inflammation, and sometimes with lung involvement. [25] [26] [27] [28]

In a three-patient case series of anti-MDA5 antibody positive dermatomyositis, all three developed interstitial lung disease, and one patient had a kidney biopsy showing focal segmental glomerulosclerosis, described as the first documented kidney involvement of this type in this setting. The same series also described other severe features such as skin ulcers, pneumomediastinum (air leaking into the chest space), and different clinical "phenotypes," underlining how variable anti-MDA5 dermatomyositis can look. [25]

A small nested case-control study of 13 people (4 with dermatomyositis plus thrombotic microangiopathy and 9 controls with dermatomyositis without it) suggested a distinct pattern in those who developed thrombotic microangiopathy: shorter time since disease onset, higher white blood cell and neutrophil counts, higher muscle enzyme levels, and lower complement blood levels. Muscle biopsy imaging in this study showed neutrophil extracellular traps, a lab signal that may relate to inflammation and clotting, but the study was too small for stronger multivariable analysis. [26]

Two single-patient reports described unusual "first presentations" that later fit with dermatomyositis. One man presented with Stevens-Johnson syndrome/toxic epidermal necrolysis-like skin loss without drug exposure and was later found to have anti-TIF1-gamma positive dermatomyositis together with diffuse large B-cell lymphoma. [27]

Another patient, a 30-year-old woman, was diagnosed with Kikuchi-Fujimoto disease (a type of lymph node inflammation) before dermatomyositis was recognized; she later achieved remission after immune-based therapies and remained in remission for 18 months in follow-up. As a case report, this describes one person and may not predict what will happen for others. [28]

For patients and caregivers, these papers mainly serve as background about the range of uncommon complications that can occur in dermatomyositis, especially during periods of high disease activity, and about the types of testing doctors may use to clarify what is happening (for example, biopsies, antibody tests, and imaging). Because most of the evidence here comes from individual cases and one small exploratory study, it cannot show how often these problems occur, who is most at risk, or which approaches work best across broader groups. Larger, multi-center studies would be needed to confirm the risk signals (such as complement levels and white blood cell patterns for thrombotic microangiopathy) and to understand rare organ involvement like kidney disease in specific antibody subtypes.

Overall, this group of papers suggests that dermatomyositis may sometimes appear after certain environmental or immune system events, but the evidence is mostly exploratory. A cross-sectional study in juvenile dermatomyositis (JDM) showed country-level differences in early-life exposures that lined up with differences in age at symptom onset, while case reports described dermatomyositis or related inflammatory muscle disease occurring after COVID-19 infection or vaccination, or alongside a later-diagnosed cancer. [29] [30] [31] [32] [33]

In the JDM comparison between Brazil and the United States (102 children total), Brazilian children developed symptoms at a younger average age and had different reported prenatal and early-life exposures, including more dust and household tobacco exposure and more frequent proximity of pregnancy and birth locations to factories or quarries. U.S. families more often reported office work and subway commuting. Because these were retrospective questionnaires and the study was not designed to test disease susceptibility, the results cannot show that any exposure caused JDM. [29]

Several single-patient reports described dermatomyositis or dermatomyositis-spectrum inflammatory myopathy after immune triggers. One 51-year-old man developed dermatomyositis about 2 months after a COVID-19 vaccine (Sinovac CoronaVac), improved after immune-suppressing medicines, and was in remission at 6 months, but a time link alone cannot prove the vaccine caused the disease. [30]

Two other case reports highlight that infection-related timing can be mixed and may not move in only one direction. One 62-year-old woman developed severe inflammatory myopathy with dermatomyositis-spectrum overlap features after a recent COVID-19 infection, including swallowing and throat involvement, and improved after immune-suppressing treatment and supportive care. In contrast, an 80-year-old person with long-standing dermatomyositis had prolonged remission and loss of previously detected autoantibodies after a severe SARS-CoV-2 infection, although a small-vessel nailfold test still suggested possible low-level disease activity. [32] [33]

Another single-patient report shows why triggers can be hard to interpret when other conditions appear later. A 73-year-old man first presented with rhabdomyolysis that evolved into inflammatory myopathy and later dermatomyositis, and he was eventually found to have anaplastic lymphoma, supporting a cancer-related (paraneoplastic) explanation even though a vaccine timing question was also discussed; earlier cancer scans had been negative. [31]

For patients and caregivers, these studies mainly provide background about how researchers are investigating possible triggers rather than providing clear, proven causes. The juvenile study suggests that patterns of early-life exposures (like dust, tobacco smoke, or industrial proximity) can differ by region and may relate to differences in when symptoms begin, but it cannot separate these exposures from other factors such as geography or socioeconomic conditions. The case reports show that dermatomyositis can appear after COVID-19 infection or vaccination in some individuals, and that cancer may be discovered later in some cases, but single-patient stories cannot tell how often this happens or whether the timing is coincidence. [29] [30] [31] [32] [33]

In this small retrospective multicenter study from Portugal, pregnancy outcomes in women with idiopathic inflammatory myopathies were closely tied to whether the mother had active disease during pregnancy. Adverse pregnancy outcomes occurred in half of pregnancies overall, but they were seen only in pregnancies complicated by disease flares, not in pregnancies where disease stayed stable. [34]

Among 12 pregnancies in 10 women, there were 7 live births and 6 adverse outcomes (4 miscarriages, 1 stillbirth, and 1 fetal growth restriction with a small-for-gestational-age newborn). No cases of preeclampsia, eclampsia, congenital anomalies, or neonatal lupus were reported in this series. The authors noted that the most severe outcomes occurred in a mother with antisynthetase syndrome and very high anti-Jo-1 antibody levels. [34]

The report also described that most pregnancies had detectable myositis-related antibodies, and that some women had lung involvement before conception. Inadvertent exposure to certain immune-suppressing drugs during pregnancy was linked to early pregnancy loss in this dataset, emphasizing that real-world medication histories can be complex in retrospective studies. [34]

For families thinking about pregnancy or currently pregnant, this study suggests that disease activity during pregnancy may be a key factor linked to pregnancy complications in people with inflammatory muscle diseases, including dermatomyositis-related conditions. Because the study was small and retrospective, it cannot estimate precise risks for an individual, and it may not capture milder or silent disease activity. The main value right now is helping clinicians and researchers frame which pregnancy-related questions to study more carefully in larger groups. [34]

Across these studies, a repeated pattern is that immune signaling linked to interferons (natural antiviral signals) looks higher than normal in dermatomyositis, especially in anti-MDA5-positive disease, and it connects to changes in how immune cells behave and how muscle cells function. Several reports also highlight muscle-intrinsic problems, including stressed mitochondria (the cell's energy makers) and activation of pathways involved in muscle repair. Most evidence here is exploratory and based on blood tests, biopsies, and lab experiments rather than direct cause-and-effect proof in people. [35] [36] [37] [38] [39] [40] [41] [42]

In untreated adult dermatomyositis, one blood study found fewer mucosal-associated invariant T (MAIT) cells in circulation, but the MAIT cells that remained looked more activated and made more interferon-gamma, with stronger changes reported in anti-MDA5-positive disease. The same study also found lower levels of certain "homing" receptors (CCR2 and CCR5), which may reflect changes in where these cells travel in the body. Together, this supports the idea that specific T-cell subsets may be unusually switched on in dermatomyositis. [38]

Two anti-MDA5-positive dermatomyositis studies linked interferon-beta signaling to stronger inflammatory cell programs. One report connected lower levels of an RNA-marking system (m6A) and lower levels of the reader protein YTHDF2 in blood immune cells with higher interferon-beta gene activity, and in lab cells, lowering YTHDF2 increased interferon-beta and turned on the JAK-STAT pathway. Another study found higher activity of PANoptosis (a combined inflammatory cell-death program) in patient blood cells, with markers increased in T cells and a key gene (ZBP1) helping drive interferon-beta-triggered PANoptosis in lab experiments. [35] [36]

In anti-MDA5-positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease, one study described weaker natural killer (NK) cell activation and reduced degranulation (a key step in killing infected or abnormal cells). The same work found that patient IgG could shift immune activity toward stronger macrophage antibody-dependent functions through a CD16-dependent mechanism in lab tests, along with changes in signaling pathways inside blood immune cells. This suggests that antibody-driven immune miscommunication may be part of the severe inflammatory pattern seen in this lung-involved subgroup. [42]

Several studies focused on what happens inside muscle itself, not just in circulating immune cells. In juvenile dermatomyositis, a translational study found a pro-inflammatory set of muscle-made signals in blood and muscle, and healthy lab-grown human muscle exposed to interferons or a viral mimic produced a similar signal pattern; CXCL9 and CXCL10 tracked with measured muscle activity in that study. Separately, an ex vivo experiment showed that serum from people with idiopathic inflammatory myopathies could directly weaken isolated mouse muscle and reduce mitochondrial respiration while increasing TNF-alpha and IL-1 beta expression, suggesting that circulating factors can rapidly affect muscle energy and strength in a lab setting. [37] [41]

Two muscle biology studies highlighted pathways tied to energy quality control and repair. In mice and muscle cells, loss of CTRP1 impaired muscle cell differentiation and disrupted mitochondrial structure and function, and lower CTRP1 levels in human muscle biopsies were linked to worse disease severity. In muscle biopsies from dermatomyositis and immune-mediated necrotizing myopathy, MuRF-1 was mainly seen in regenerating (repairing) muscle fibers, and lab knockdown of MuRF-1 reduced muscle cell proliferation and fusion, suggesting MuRF-1 may support repair processes even though this does not prove it improves outcomes in patients. [39] [40]

For patients and caregivers, this body of work mainly helps explain why dermatomyositis can involve both immune overactivity and muscle weakness: immune signals like interferon-related pathways may amplify inflammation, while muscle cells show signs of energy stress and active repair. Some results are specific to anti-MDA5-positive disease, including studies that connect interferon-beta to inflammatory cell-death programs and altered NK cell and antibody-related immune functions that may relate to severe lung involvement. Many results come from small human cohorts and lab models, so it remains uncertain which changes are causes versus effects of disease, and which markers will prove most useful for tracking disease activity across different dermatomyositis subtypes. [35] [36] [42] [37]